Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

Summary

This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C. The study will be divided into two parts: * SAD cohorts * MAD cohorts

Timeline

Start

2023-04-27

Primary completion

2024-02-23

Completion

2024-02-23

Drugs

Indications